Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 22;10(3):520.
doi: 10.3390/biomedicines10030520.

Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity

Carmine Rocca  1 , Ernestina Marianna De Francesco  2 , Teresa Pasqua  3 , Maria Concetta Granieri  1 , Anna De Bartolo  1 , Maria Eugenia Gallo Cantafio  4 , Maria Grazia Muoio  2 , Massimo Gentile  5 , Antonino Neri  6   7 , Tommaso Angelone  1   8 , Giuseppe Viglietto  4 , Nicola Amodio  4
Affiliations
Review

Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity

Carmine Rocca et al. Biomedicines. .

Abstract

Mitochondria are key organelles for the maintenance of myocardial tissue homeostasis, playing a pivotal role in adenosine triphosphate (ATP) production, calcium signaling, redox homeostasis, and thermogenesis, as well as in the regulation of crucial pathways involved in cell survival. On this basis, it is not surprising that structural and functional impairments of mitochondria can lead to contractile dysfunction, and have been widely implicated in the onset of diverse cardiovascular diseases, including ischemic cardiomyopathy, heart failure, and stroke. Several studies support mitochondrial targets as major determinants of the cardiotoxic effects triggered by an increasing number of chemotherapeutic agents used for both solid and hematological tumors. Mitochondrial toxicity induced by such anticancer therapeutics is due to different mechanisms, generally altering the mitochondrial respiratory chain, energy production, and mitochondrial dynamics, or inducing mitochondrial oxidative/nitrative stress, eventually culminating in cell death. The present review summarizes key mitochondrial processes mediating the cardiotoxic effects of anti-neoplastic drugs, with a specific focus on anthracyclines (ANTs), receptor tyrosine kinase inhibitors (RTKIs) and proteasome inhibitors (PIs).

Keywords: anticancer therapy; cardiotoxicity; heart failure; mitochondrial function.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of major events leading to mitochondrial dysfunction during ANT (DOX)-induced cardiotoxicity. ANT: anthracycline; DOX: doxorubicin; ROS: reactive oxygen species; RNS: reactive nitrogen species; ERS: endoplasmic reticulum stress; Top2β: topoisomerase 2β; ETC: electron transport chain; mtDNA: mitochondrial DNA.
Figure 2
Figure 2
Schematic representation of mitochondrial dynamics alterations induced by ANT (DOX) leading to cardiotoxicity. ANT: anthracycline; DOX: doxorubicin; ROS: reactive oxygen species; MFN1: mitofusin-1; MFN2: mitofusin-2; OPA1: optic atrophy 1; DRP1: dynamin-related protein 1; Midivi-1: mitochondrial division inhibitor-1; mPTP: mitochondrial permeability transition pore; cyt c: cytochrome c.
Figure 3
Figure 3
Proposed mechanism of cardiac mitochondrial alterations secondary to PIs and RTKIs exposure. PIs: Proteasome inhibitors; RTKIs: Receptor tyrosine kinase inhibitors; ETC: electron transport chain; ROS: reactive oxygen species; mPTP: mitochondrial permeability transition pore; cyt c: cytochrome c.
See this image and copyright information in PMC

References

    1. Pasqua T., Rocca C., Giglio A., Angelone T. Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. J. Clin. Med. 2021;10:721. doi: 10.3390/jcm10040721. - DOI - PMC - PubMed
    1. Nguyen B.Y., Ruiz-Velasco A., Bui T., Collins L., Wang X., Liu W. Mitochondrial function in the heart: The insight into mechanisms and therapeutic potentials. J. Cereb. Blood Flow Metab. 2019;176:4302–4318. doi: 10.1111/bph.14431. - DOI - PMC - PubMed
    1. Cadete V.J., Vasam G., Menzies K.J., Burelle Y. Mitochondrial quality control in the cardiac system: An integrative view. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2019;1865:782–796. doi: 10.1016/j.bbadis.2018.11.018. - DOI - PubMed
    1. Chistiakov D.A., Shkurat T.P., Melnichenko A.A., Grechko A.V., Orekhov A.N. The role of mitochondrial dysfunction in cardiovascular disease: A brief review. Ann. Med. 2018;50:121–127. doi: 10.1080/07853890.2017.1417631. - DOI - PubMed
    1. Marín-García J., Akhmedov A.T. Mitochondrial dynamics and cell death in heart failure. Heart Fail. Rev. 2016;21:123–136. doi: 10.1007/s10741-016-9530-2. - DOI - PubMed

LinkOut - more resources